Effect of Bioptron on Primary Dysmenorrhea

Launched by CAIRO UNIVERSITY · Dec 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called Bioptron on women who experience primary dysmenorrhea, which is a medical term for painful menstrual cramps. The researchers want to find out if Bioptron can help reduce pain levels and improve the quality of life for women suffering from this condition. They will measure pain using a special tool and look at hormone levels in the blood, along with using questionnaires to understand how menstrual pain affects daily life.

To participate in the study, women need to be between 18 and 24 years old, have moderate to severe pain from menstrual cramps, and be diagnosed with primary dysmenorrhea by a doctor. They should also have regular periods and a body mass index (BMI) below 30. However, some women may not be eligible, including those with certain medical conditions, those who have used hormonal birth control, or those who are professional athletes. If you qualify and decide to join, you can expect to be part of a study that aims to improve treatments for menstrual pain, contributing valuable information to women's health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • All females will be clinically diagnosed by the gynecologist with primary dysmenorrhea.
• • Self-reported history of PD, at least moderate pain due to menstrual cramps (\>4 on VAS)
• • They have moderate symptoms of PD on the WaILDD questionnaire, (5-12) Teheran et al., 2018).
• • Their ages will be ranged from 18-24 years old.
• • Their BMI will be less than 30 kg/m².
• • Being a virgin.
• • Having regular menstruation for the last 6 months (every 28-30 days with no intermittent bleeding).
• • Voluntary acceptance to participate in the study.
• B) Exclusion Criteria:
• Participants will be excluded if they have:
• • Musculoskeletal or neurological disorders.
• • Patients with a history of phototherapy allergy.
• • Professional athletes (Jill et al., 2012).
• • Secondary dysmenorrhea pathology such as (endometriosis, fibroids, adenomyosis, and pelvic inflammatory disease)
• • Menstrual irregularity.
• • Using hormonal contraception (such as contraceptives or injections).